Maryanne Mufford , Dennis van der Meer , Dan Stein , Rajendra Morey
{"title":"THE SHARED GENETIC ARCHITECTURE OF PTSD AND BRAIN MORPHOLOGY","authors":"Maryanne Mufford , Dennis van der Meer , Dan Stein , Rajendra Morey","doi":"10.1016/j.euroneuro.2025.08.499","DOIUrl":null,"url":null,"abstract":"<div><div>Post-traumatic stress disorder (PTSD) has been associated with alterations in global, subcortical, and cortical brain morphology, as well as regional white matter measures. However, the genetic mechanisms contributing to these brain differences in PTSD remain unknown. Investigating the shared genetic architecture of PTSD and brain morphology may help uncover overlapping biological pathways, clarify aspects of PTSD neurobiology, and improve the power to detect genetic loci for PTSD by leveraging information from genetically correlated brain traits.</div><div>We used GWAS summary statistics from the Psychiatric Genomics Consortium (PGC-PTSD Freeze 3; N = 1,222,882) and conducted both univariate and multivariate GWAS of brain morphology in the UK Biobank (N = 33,735). The brain phenotypes included 196 global and regional measures spanning cortical thickness, surface area, subcortical volume, and white matter microstructure. Multivariate GWAS was performed using MOSTest to identify shared genetic components across brain traits. Genetic correlation between PTSD and brain phenotypes was estimated using linkage disequilibrium score regression (LDSC), and conditional false discovery rate (condFDR) analysis was applied to detect shared loci, including those with mixed effect directions. We further assessed pleiotropy using MiXer, which estimates the number of causal variants shared between traits. To integrate genetic risk across both domains, we applied PleioPGS, a polygenic scoring method that incorporates pleiotropic signals from both PTSD and brain morphology, to estimate the variability explained for PTSD and brain morphology in 22 independent cohorts from the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium.</div><div>This study examines the extent to which common genetic variants contribute jointly to PTSD and brain structure, and whether integrating genetic information from both sources enhances our ability to identify novel biological mechanisms. Findings from this work will identify genetically informed imaging biomarkers and deepen insight into neurobiological pathways associated with PTSD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"99 ","pages":"Page 22"},"PeriodicalIF":6.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X25006571","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Post-traumatic stress disorder (PTSD) has been associated with alterations in global, subcortical, and cortical brain morphology, as well as regional white matter measures. However, the genetic mechanisms contributing to these brain differences in PTSD remain unknown. Investigating the shared genetic architecture of PTSD and brain morphology may help uncover overlapping biological pathways, clarify aspects of PTSD neurobiology, and improve the power to detect genetic loci for PTSD by leveraging information from genetically correlated brain traits.
We used GWAS summary statistics from the Psychiatric Genomics Consortium (PGC-PTSD Freeze 3; N = 1,222,882) and conducted both univariate and multivariate GWAS of brain morphology in the UK Biobank (N = 33,735). The brain phenotypes included 196 global and regional measures spanning cortical thickness, surface area, subcortical volume, and white matter microstructure. Multivariate GWAS was performed using MOSTest to identify shared genetic components across brain traits. Genetic correlation between PTSD and brain phenotypes was estimated using linkage disequilibrium score regression (LDSC), and conditional false discovery rate (condFDR) analysis was applied to detect shared loci, including those with mixed effect directions. We further assessed pleiotropy using MiXer, which estimates the number of causal variants shared between traits. To integrate genetic risk across both domains, we applied PleioPGS, a polygenic scoring method that incorporates pleiotropic signals from both PTSD and brain morphology, to estimate the variability explained for PTSD and brain morphology in 22 independent cohorts from the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium.
This study examines the extent to which common genetic variants contribute jointly to PTSD and brain structure, and whether integrating genetic information from both sources enhances our ability to identify novel biological mechanisms. Findings from this work will identify genetically informed imaging biomarkers and deepen insight into neurobiological pathways associated with PTSD.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.